In the high-stakes world of pharmaceutical development, the journey from laboratory bench to patient bedside is fraught with attrition. However, a silent crisis is unfolding within the R&D departments of the world’s largest drug companies: more than 5,000 potentially life-altering rare disease treatments are currently sitting idle on shelves. These are not necessarily failed drugs, but rather "orphan" assets—candidates that were sidelined due to shifting corporate priorities, portfolio realignments, or the simple arithmetic of commercial viability rather than scientific failure.
Annette Bakker, PhD, CEO of the Children’s Tumor Foundation (CTF), is spearheading a movement to change this narrative. By positioning the nonprofit as a bridge between dormant corporate intellectual property and the patients who desperately need it, CTF is demonstrating that the next blockbuster treatment for a rare disease might already exist—it just needs a new owner.
The Anatomy of a Shelved Asset: Why Good Science Goes Quiet
To understand why thousands of viable candidates are gathering dust, one must look at the mechanics of Big Pharma. When major pharmaceutical corporations acquire smaller biotech firms, they are often hunting for a specific "crown jewel" asset. Once the acquisition is complete, the remaining portfolio is frequently rationalized. If a drug candidate doesn’t fit the company’s new therapeutic focus or isn’t projected to generate blockbuster-level revenue, it is deprioritized, shelved, or effectively buried.
"Shelved assets are our primary focus because they have already undergone rigorous development," explains Bakker. "A company has often spent hundreds of millions of dollars on them, including preclinical work and Phase 1 safety testing, only to write them off as a loss. If we could take those assets and move them directly into clinical trials, we bypass years of foundational legwork."
The challenge, however, is institutional inertia. Often, when a biotech company folds or a partnership dissolves, the data associated with those assets becomes inaccessible or lost in the shuffle. This "data graveyard" represents an enormous waste of scientific capital, human effort, and financial investment.
A Proven Blueprint: The SpringWorks Success Story
The efficacy of CTF’s model was validated in the case of Gomekli (nirogacestat). Bakker recognized that a MEK inhibitor—a class of drugs that had shown promise in treating neurofibromatosis (NF), a group of genetic conditions that cause tumors to grow on nerves—was languishing in Pfizer’s portfolio.
Through persistent advocacy and strategic collaboration, Bakker engaged with Pfizer leadership, including Freda Lewis-Hall and Lara Sullivan. Her pitch was simple but compelling: if the asset didn’t fit Pfizer’s commercial model, why not license it to a spin-off entity?
This negotiation resulted in the creation of SpringWorks Therapeutics in 2017. The gamble paid off: Gomekli eventually secured FDA approval, and SpringWorks was later acquired by Merck KGaA in a deal valued at $3.4 billion. It stands as a beacon of what is possible when nonprofit advocacy meets corporate flexibility. Yet, as Bakker notes, the current process is difficult to scale. "We are looking for these champions in other companies, but the doors are often closed," she admits.
The Rare Disease Paradox: Why Recruitment is the Ultimate Hurdle
Beyond the acquisition of the drug itself, the pathway to approval for rare disease therapies is uniquely treacherous. In the rare disease space, patient populations are small, geographically dispersed, and often underserved by traditional clinical trial infrastructure.
"Everything you do in drug discovery is ten times harder in rare disease," Bakker says. For a condition like NF, which affects roughly 1 in 2,000 people, the subset of patients with inoperable plexiform neurofibromas is even smaller. Filling a clinical trial for a patient cohort this thin can take years, inflating costs and delaying access to life-saving medicine.
This is where the unique value proposition of a patient-advocacy organization comes into play. Unlike a for-profit entity, the Children’s Tumor Foundation acts as a hub for the patient community. By maintaining a robust, longitudinal network of patients, they are able to facilitate recruitment, identify trial sites, and provide the "human" data that regulators now increasingly demand.
The CTF Ecosystem: Building a Preclinical Engine
To ensure that once an asset is acquired, it doesn’t languish again, the CTF has developed a sophisticated preclinical hub. This ecosystem allows the foundation to rapidly validate drug candidates through a growing library of preclinical models. By de-risking the science before it reaches the clinic, CTF makes these assets more attractive to potential commercial partners and investors.
The goal is to create a seamless "conveyor belt" for drug development:
- Asset Identification: Scouring industry databases and partnerships for shelved candidates.
- Licensing and Transfer: Negotiating the transfer of IP to spin-offs or research entities.
- Preclinical Validation: Utilizing the CTF’s proprietary research models to confirm efficacy.
- Clinical Execution: Leveraging the patient network to accelerate trial enrollment.
This structure allows the foundation to act as a "de-risking engine," absorbing the early-stage scientific uncertainty that keeps corporate boardrooms hesitant.
Official Responses and Industry Implications
The pharmaceutical industry is notoriously risk-averse, particularly regarding public-private partnerships involving "written-off" assets. However, the success of the SpringWorks model has created a template for "venture philanthropy."
Experts in the field of drug discovery suggest that the "5,000 shelved assets" figure is likely a conservative estimate. As the cost of clinical trials continues to climb, the pressure to divest from non-core assets will only increase. For Big Pharma, the challenge is not just technical but cultural. The "not invented here" (NIH) syndrome often prevents companies from acknowledging that an external entity could manage a shelved asset better than they could.
However, the tide may be turning. With the rise of precision medicine and the increasing influence of patient advocacy groups, pharmaceutical executives are finding it harder to justify letting potentially life-saving compounds sit idle. Transparency initiatives, such as the public disclosure of trial data, are also making it easier for organizations like CTF to identify which "dead" assets might, in fact, be "sleeping giants."
Future Outlook: A New Paradigm for Drug Development
The model pioneered by the Children’s Tumor Foundation represents a fundamental shift in how we think about drug discovery. Instead of relying solely on the internal R&D pipelines of monolithic corporations, the future of rare disease treatment may lie in a decentralized, collaborative model.
As we look to the future, three key factors will determine the success of this approach:
- Cultural Change: Pharma companies must view the transfer of shelved assets not as a loss of value, but as a form of CSR (Corporate Social Responsibility) that can also yield financial returns through milestone payments or equity stakes.
- Data Accessibility: Open science initiatives must ensure that when a company decides to shelve a project, the associated data is made available to the research community.
- Patient-Centric Infrastructure: The success of CTF proves that the most important resource in rare disease research is not the drug itself, but the patients who participate in the clinical trials.
The mission is clear: by transforming "shelved" assets into "active" ones, we can shorten the distance between a discovery in a lab and a solution for a patient. In the landscape of rare disease, where every day counts, this is more than just an efficient business model—it is a moral imperative.
"We have the tools, we have the models, and we have the patients," concludes Bakker. "Now, we just need the industry to open the doors."
About the Author
